Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting
27 April 2023 - 9:00PM
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage
biotechnology company pioneering the development of a new class of
programmable epigenomic mRNA medicines, today announced that it
will present new preclinical data related to its MYC-HCC and
MYC-NSCLC programs at the upcoming American Society of Clinical
Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois,
June 2 – 6, 2023.
Details for the ASCO 2023 Annual Meeting poster
presentation are as follows:
Title: Effect of MYC-targeting Programmable
Epigenetic mRNA Therapeutics on TME and Immunotherapy
ResponsesAbstract #: 4116Session
Information: Gastrointestinal Cancers – Gastroesophageal,
Pancreatic, and HepatobiliaryDate and Time: June
5, 2023, from 8:00 a.m. to 11:00 a.m. CDT
The poster will be made available on the Omega website at
https://omegatherapeutics.com/our-science/#publications-research at
the same time as the presentation.
About Omega TherapeuticsOmega Therapeutics is a
clinical-stage biotechnology company pioneering the development of
a new class of programmable epigenomic mRNA medicines to treat or
cure a broad range of diseases. By pre-transcriptionally modulating
gene expression, Omega’s approach enables precision epigenomic
control of nearly all human genes, including historically
undruggable and difficult-to-treat targets, without altering native
nucleic acid sequences. Founded in 2017 by Flagship Pioneering
following breakthrough research by world-renowned experts in the
field of epigenetics, Omega is led by a seasoned and accomplished
leadership team with a track record of innovation and operational
excellence. The Company is committed to revolutionizing genomic
medicine and has a diverse pipeline of therapeutic candidates
derived from its OMEGA platform spanning oncology, regenerative
medicine, multigenic diseases including immunology, and select
monogenic diseases.
For more information, visit omegatherapeutics.com, or
follow us on Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding upcoming events
and presentations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: the novel technology on which our product candidates are
based makes it difficult to predict the time and cost of
preclinical and clinical development and subsequently obtaining
regulatory approval, if at all; the substantial development and
regulatory risks associated with epigenomic controllers due to the
novel and unprecedented nature of this new category of medicines;
our limited operating history; the incurrence of significant losses
and the fact that we expect to continue to incur significant
additional losses for the foreseeable future; our need for
substantial additional financing; our investments in research and
development efforts that further enhance the OMEGA platform, and
their impact on our results; uncertainty regarding preclinical
development, especially for a new class of medicines such as
epigenomic controllers; potential delays in and unforeseen costs
arising from our clinical trials; the fact that our product
candidates may be associated with serious adverse events,
undesirable side effects or have other properties that could halt
their regulatory development, prevent their regulatory approval,
limit their commercial potential, or result in significant negative
consequences; the impact of increased demand for the manufacture of
mRNA and LNP-based vaccines to treat COVID-19 on our development
plans; difficulties manufacturing the novel technology on which our
OEC candidates are based; our ability to adapt to rapid and
significant technological change; our reliance on third parties for
the manufacture of materials; our ability to successfully acquire
and establish our own manufacturing facilities and infrastructure;
our reliance on a limited number of suppliers for lipid excipients
used in our product candidates; our ability to advance our product
candidates to clinical development; and our ability to obtain,
maintain, enforce and adequately protect our intellectual property
rights. These and other important factors discussed under the
caption "Risk Factors" in our Annual Report on Form 10-K for the
year ended December 31, 2022, and our other filings with the SEC,
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
CONTACT
Investor contact:
Eva Stroynowski
617.949.4370
estroynowski@omegatx.com
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Omega Therapeutics (NASDAQ:OMGA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Omega Therapeutics (NASDAQ:OMGA)
Historical Stock Chart
From Jul 2023 to Jul 2024